MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Reserpine hydrochloride

CAS No. : 16994-56-2

MCE 站：Reserpine hydrochloride

产品活性：Reserpine (hydrochloride) 是囊泡单胺转运蛋白 2 (VMAT2) 的抑制剂。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Monoamine Transporter

In Vitro: Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). Reserpine hydrochloride displays a significant on the density of dopamine D1 receptors (F_2,12=8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change. IC₅₀ values of 43.9 and 54.9 μM are obtained after 1 day of treatment with Reserpine hydrochloride in JB6 P+ and HepG2-C8 cells, respectively. Reserpine hydrochloride induces luciferase activity in a dose-dependent manner at concentrations ranging from 5 to 50 μM, and no significant induction is observed at concentrations lower than 5 μM. Results demonstrate that Reserpine hydrochloride (2.5 to 10 μM) also increases the protein expression of Nrf2, HO-1, and NQO1. Reserpine hydrochloride at concentrations of 2.5 to 10 μM decreases the mRNA expression of DNMT1, DNMT3a, and DNMT3b in a concentration-dependent manner in JB6 P+ cells after 7 days of treatment. Reserpine hydrochloride at 10 μM generates a significant difference for DNMT3a expression (p<0.05).

In Vivo: Withdrawal (48 h) from chronic (14-day) but not acute Reserpine hydrochloride administration in a dose of 0.2 mg/kg i.p. produces a significant reduction of the immobility time (F_2,18=3.68, p<0.05), but increases the climbing time (F_2,18=4.48, p<0.02), and does not change the swimming time (F_2,18=1.78; NS) in the forced swim test (FST) in rats. Reserpine hydrochloride at a dose of 5 mg/kg body weight produces significant increase in the urinary excretion profile of vanillylmandelic acid (VMA) compare to control animals. The amount of 5-hydroxyindoleacetic acid (5-HIAA) excreted in animals treated with Reserpine is found to be more than in the control. Dose dependent hypotension is observed with Reserpine hydrochloride. Reserpine hydrochloride at doses of 0.5, 1, 5, 10 and 15 μg/kg produce significant (p<0.01) reduction in blood pressure compare to control.

相关产品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Traditional Chinese Medicine Monomer Library  |  FDA Approved & Pharmacopeial Drug Library  |  Alkaloids Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Reserpine  |  Tetrabenazine  |  Radafaxine hydrochloride  |  NBI-98782  |  Nisoxetine hydrochloride  |  Vanilpyruvic acid  |  13-Hydroxyisobakuchiol  |  FFN200 dihydrochloride  |  (+)-Tetrabenazine D6

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。